CClinicalTrials.gg
Sign In
CompletedNCT00568204Mexyn-AUpdated Oct 17, 2013

Study of Effectiveness of Mexyn-A

An interventional study of Mexyn-A in Pruritus, sponsored by Evangelical Synod Medical Centre. Completed at 1 site in Egypt. Open to participants aged 5 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-10-17.

Sponsored by Evangelical Synod Medical Centre · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
279
Allocation
Not applicable
Ages
5 Years to 80 Years
Sex
All
01

Study summary

Atomised Methoxymethane-in-Aqua (MEXYN-A) a new topical self-chilled, non-steroidal, non-flammable, pressurised spray which embodies in one simultaneous application, most of the currently recognised and effective chemical, mechanical and thermal anti-pruritic therapies and hydrotherapy.

Read the detailed description

The primary clinical endpoint was to establish MEXYN-A efficacy and safety in abolishing or reducing pruritus related to cutaneous diseases, insect bites and poison ivy, within few seconds of the application. The secondary endpoint was to measure the itch free period as a result of the new intervention.

02

Conditions studied

  • Pruritus

Browse trials for

Keywords

  • pruritus, itching, mexyn-a, clearitch, magicool-plus
03

In context

Pruritus

354 studies on the registry are indexed under Pruritus; 74 are open to participants now.

This study's enrollment of 279 is above the median of 60 across 294 interventional studies indexed under Pruritus.

Browse Pruritus studies →

Lead sponsor

This is the only study on the registry with Evangelical Synod Medical Centre as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
5 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Patients suffering from severe itching due to : Atopic Dermatitis, contact dermatitis, psoriasis, urticaria, xerosis, prickly heat, genital pruritus, chicken pox, aquagenic pruritus, lichen planus, poison ivey, insect bites.
  • Past experience with the use of at least one conventional medication for pruritus or conventional medication for the same disorder patients suffered.

Exclusion criteria

Exclusion Criteria:

  • Patients who have taken any anti-pruritic drug during the month prior to participation.
  • Patients who have taken drugs for any reason for 2 days prior to participating in the study.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
279 participants (actual)

Study arms

  • Experimental
    1

    Mexyn-A

    Device: Mexyn-A

Interventions

  • DeviceMexyn-A

    Atomised topical self-chilled pressurised spray

    Also known as: Clearitch, Itcharret, itchclear, Magicool-Plus

06

What researchers measure

Primary outcomes

  1. Treating Pruritus

    Time frame: three days

Secondary outcomes

  1. measuring itch-free period after applying the new treatment, effect on sleep disturbance

    Time frame: three days

07

Study locations

1 site
  • Evangelical Synod Medical Centre
    Cairo, 11111, Egypt
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 17, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00568204
Lead sponsor
Evangelical Synod Medical Centre
First posted
Dec 5, 2007
Start date
Mar 2002
Completion
Sep 2005
Last update
Oct 17, 2013

Study contacts

Ihab Akhnoukh
principal investigator · Evangelical Synod Medical Centre
Ashraf Khella
study director · Harpur Memorial Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Pruritus→

Start the discussion